暫無數據
代碼股票名稱
最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
美股市場個股詳情
CLLS Cellectis
- 2.560
- 0.0000.00%
收盤價 04/30 16:00 (美東)
1.84億總市值-1446市盈率TTM
2.560最高價2.500最低價9080股成交量2.520今開2.560昨收2.29萬成交額0.02%換手率虧損市盈率(靜)7195.35萬總股本3.77452周最高2.18市淨率1.10億流通值0.96352周最低--股息TTM4308.50萬流通股50.000歷史最高--股息率TTM2.34%振幅0.963歷史最低2.523平均價1股每手
盤前分時
- 5日
- 日K
- 周K
- 月K
- 季K
- 年K
資金分布
單位: --
資金流向
實時日周月
暫無數據
新聞
分析師提供有關醫療保健公司的見解：Healthequity（HQY）、Cellectis SA（CLLS）和Idexx實驗室（IDXX）
巴克萊銀行仍然是Cellectis SA（CLLS）的獲得買入評級
快訊 | Cellectis2023年第四季度GAAP每股收益（0.64美元）未達到預期（0.26美元），銷售額爲19.9億美元，未達到1626.3萬美元的預期
Cellectis認爲，Cash Runway將延長至2025年第三季度，在合併財務報表發佈後，將能夠運營至少12個月
Cellectis認爲，Cash Runway將延長至2025年第三季度，在合併財務報表發佈後，將能夠運營至少12個月
Cellectis 第四季度虧損/64c >CLLS
Cellectis 第四季度虧損/64c >CLLS
新聞稿：Cellectis公佈了2023年第四季度和全年財務業績
Cellectis 公佈了 2023 年第四季度和全年財務業績--在美國發布的 NATHALI-01 的初步結果和 BALLI-01 I 期臨床研究的最新結果
評論
$Cellectis(CLLS.US$
NEWS
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Cellectis presents novel TALEN editing processes enabling highly efficient gene correction and gene insertion in HSPCs, showcasing the potential and versatility of the technology for gene therapy. The company will present first data exploring these processes at ASGCT. The editing approaches could revolutionize the treatment of metabolic and neurologica...
NEWS
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Cellectis presents novel TALEN editing processes enabling highly efficient gene correction and gene insertion in HSPCs, showcasing the potential and versatility of the technology for gene therapy. The company will present first data exploring these processes at ASGCT. The editing approaches could revolutionize the treatment of metabolic and neurologica...
$Cellectis(CLLS.US$
NEWS
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Cellectis (NASDAQ: CLLS) announces a breakthrough in gene-editing therapy with the publication of a new research paper. The study demonstrates the potential of TALEN-mediated intron editing in HSPCs for targeted transgene expression, offering new treatment possibilities for metabolic and neurological diseases.
NEWS
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Cellectis (NASDAQ: CLLS) announces a breakthrough in gene-editing therapy with the publication of a new research paper. The study demonstrates the potential of TALEN-mediated intron editing in HSPCs for targeted transgene expression, offering new treatment possibilities for metabolic and neurological diseases.
1
$Cellectis(CLLS.US$ Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
3 MINUTES AGO, 4:30 PM EDT
VIA GLOBENEWSWIRE
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that...
3 MINUTES AGO, 4:30 PM EDT
VIA GLOBENEWSWIRE
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that...
Jean Pierre Garnier, Cellectis Chairman, thanked shareholders for supporting the Additional Investment and welcomed Mr. Dunoyer and Dr. Rivers to the board, praising their pharma industry experience.
1
$Cellectis(CLLS.US$ 今天會見到4塊嗎😎
已翻譯
閱讀更多
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅